The aim of the Italian Registry of Malnutrition in Oncology (IRMO) is to set up a digital register of newly diagnosed or treated oncologic patients to monitor their nutritional status, early identify malnutrition and investigate the implications of nutritional support management. In particular, this project aims to establish a prospective cohort of cancer patients in order to investigate the effects of nutritional status and management on overall survival (OS) and progression free survival (PFS), and analyse the effects of the nutritional management and support on patients' symptoms and QoL.
This is a multicentric longitudinal observational study on a cohort of newly diagnosed cancer patients, candidate for active treatment. In Italy, no reliable data are still available with regards to the actual implementation of adequate nutritional support management in cancer patients; only "real-world" data collected by administrative databases are available in the context of nutrition in oncology, and this somehow limits the possibility to interpret the evidence from a clinical point of view. Hence, the purpose of the intestigators is to collect "real world" clinical data on malnutrition in oncology at the national level, in order to strengthen the evidence and concretely improve nutritional care practices in oncology.
Study Type
OBSERVATIONAL
Enrollment
1,500
Cohort observational
IRCCS Istituto Tumori Giovanni Paolo II,
Bari, BA, Italy
NOT_YET_RECRUITINGIRCCS Saverio De Bellis
Castellana Grotte, BA, Italy
RECRUITINGIstituto Ortopedico Rizzoli
Bologna, BO, Italy
RECRUITINGIstituto Romagnolo per lo Studio dei Tumori "Dino Amadori" IRCCS
Meldola, FC, Italy
RECRUITINGIRCCS Ospedale Policlinico San Martino
Genova, GE, Italy
NOT_YET_RECRUITINGIRCCS Ospedale San Raffaele, Milano
Milan, MI, Italy
RECRUITINGCentro di Riferimento Oncologico
Aviano, PN, Italy
RECRUITINGIOV Istituto Oncologico Veneto
Padova, PV, Italy
RECRUITINGAUSL IRCCS Reggio-Emilia
Reggio Emilia, RE, Italy
RECRUITINGIDI IRCCS - Istituto Dermopatico dell'Immacolata
Roma, RM, Italy
RECRUITING...and 6 more locations
Overall survival
Percentage of patients who are alive.
Time frame: 1 year
Progression-free survival
Percentage of patients who are free from tumor progression.
Time frame: 1 year and 2 years
Treatment toxicity
Treatment-related severe adverse event (grade \> or =3) according to Common Terminology Criteria for Adverse Events (CTCAE v5.0) and toxicity resulting in any treatment delay or dose reduction.
Time frame: 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.